Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
British Journal of Haematology
|
June 27, 2007
Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK
Monica Hecht, Ulrike Heider, Martin Kaiser, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 27, 2006
Angiogenesis in multiple myeloma
Christian Jakob, Jan Sterz, Ivana Zavrski, et al.
Haematologica
|
February 8, 2006
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma
Martin Kaiser, Ivana Zavrski, Jan Sterz, et al.
Expert Opinion on Investigational Drugs
|
May 22, 2008
The potential of proteasome inhibitors in cancer therapy
Jan Sterz, Ivana von Metzler, Jens-Claus Hahne, et al.
European Journal of Haematology
|
December 14, 2005
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma
Ulrike Heider, Martin Kaiser, Jan Sterz, et al.
Anti-Cancer Drugs
|
August 24, 2006
Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma
Jan Eucker, Jan Sterz, Holger Krebbel, et al.
European Journal of Haematology
|
April 9, 2010
BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma
Jan Sterz, Christian Jakob, Ulrike Kuckelkorn, et al.
European Journal of Haematology
|
February 8, 2012
The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases
Britta Lamottke, Martin Kaiser, Maren Mieth, et al.
Clinical Lymphoma & Myeloma
|
December 3, 2009
Serum levels of total-RANKL in multiple myeloma
Christian Jakob, Andrea Goerke, Evangelos Terpos, et al.
European Journal of Haematology
|
November 17, 2007
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma
Ulrike Heider, Ivana von Metzler, Martin Kaiser, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
British Journal of Haematology
|
June 27, 2007
Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK
Monica Hecht, Ulrike Heider, Martin Kaiser, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 27, 2006
Angiogenesis in multiple myeloma
Christian Jakob, Jan Sterz, Ivana Zavrski, et al.
Haematologica
|
February 8, 2006
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma
Martin Kaiser, Ivana Zavrski, Jan Sterz, et al.
Expert Opinion on Investigational Drugs
|
May 22, 2008
The potential of proteasome inhibitors in cancer therapy
Jan Sterz, Ivana von Metzler, Jens-Claus Hahne, et al.
European Journal of Haematology
|
December 14, 2005
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma
Ulrike Heider, Martin Kaiser, Jan Sterz, et al.
Anti-Cancer Drugs
|
August 24, 2006
Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma
Jan Eucker, Jan Sterz, Holger Krebbel, et al.
European Journal of Haematology
|
April 9, 2010
BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma
Jan Sterz, Christian Jakob, Ulrike Kuckelkorn, et al.
European Journal of Haematology
|
February 8, 2012
The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases
Britta Lamottke, Martin Kaiser, Maren Mieth, et al.
Clinical Lymphoma & Myeloma
|
December 3, 2009
Serum levels of total-RANKL in multiple myeloma
Christian Jakob, Andrea Goerke, Evangelos Terpos, et al.
European Journal of Haematology
|
November 17, 2007
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma
Ulrike Heider, Ivana von Metzler, Martin Kaiser, et al.
Page
of 2